Daclatasvir plus sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison

被引：6
|
作者：
Swallow, Elyse [1 ]
Song, Jinlin [1 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Kelley, Caroline [1 ]
Mu, Fan [1 ]
Kim, Soomi [1 ]
Noviello, Stephanie [2 ]
Signorovitch, James [1 ]
机构：
[1] Anal Grp Inc, 111 Huntington Ave,10th Floor, Boston, MA 02199 USA
[2] Bristol Myers Squibb Co, 100 Nassau Pk Blvd, Princeton, NJ 08540 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2016年 / 5卷 / 02期
关键词：
daclatasvir; hepatitis C genotype 3; matching-adjusted indirect comparison; peginterferon; ribavirin; sofosbuvir; SUSTAINED VIROLOGICAL RESPONSE; PEGINTERFERON ALPHA-2A; VIRUS; RIBAVIRIN; INFECTION;
D O I：
10.2217/cer.15.49
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3. Patients & methods: Clinical trials of SOF + R or A/R were identified in systematic literature reviews. The DCV+ SOF population was adjusted via propensity score weighting to match average baseline characteristics to those reported for the comparator regimens. Results: The SVR12 rate was similar between DCV + SOF and SOF + R, and significantly higher with DCV + SOF than A/R. Rates of discontinuation due to AEs were similar or significantly lower in patients treated with DCV + SOF than SOF + R or A/R. Conclusion: With its high efficacy and improved tolerability, DCV + SOF is an important treatment for hepatitis C genotype 3.
引用
收藏
页码：129 / 139
页数：11
相关论文
共 50 条
  • [41] Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Singh, Erin
    Zhou, Zheng-Yi
    Sievert, Mark
    Taiji, Riley
    CANCER MEDICINE, 2023, 12 (07): : 8005 - 8017
  • [42] Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4
    El-Khayat, H.
    Fouad, Y.
    Mohamed, H. I.
    El-Amin, H.
    Kamal, E. M.
    Maher, M.
    Risk, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) : 674 - 679
  • [43] Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
    Joharji, Hala
    Alkortas, Delal
    Ajlan, Aziza
    Ahmed, Mohamed
    Al-Ashgar, Hamad
    Al-Quaiz, Mohammed
    Broering, Dieter
    Al-Sebayel, Mohammed
    Elsiesy, Hussien
    Alkhail, Faisal A.
    Al-Hamoudi, Waleed K.
    De Vol, Edward
    Almuhayshir, Epi Amirah
    Al-Jedai, Ahmed
    HEALTH SCIENCE REPORTS, 2023, 6 (01)
  • [44] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Choy, Ernest H.
    Thom, Howard
    Kalyvas, Chrysostomos
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
    Armstrong, April W.
    Soliman, Ahmed M.
    Gisondi, Paolo
    Fang, Siran
    Patel, Manish
    Strober, Bruce
    DERMATOLOGY AND THERAPY, 2024, 14 (11) : 3071 - 3081
  • [46] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Mease, Philip J.
    McInnes, Iain B.
    Nash, Peter
    Thom, Howard
    Hunger, Matthias
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [47] Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
    Strand, Vibeke
    McInnes, Iain
    Mease, Philip
    Nash, Peter
    Thom, Howard
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Gandhi, Kunal
    Pricop, Luminita
    Jugl, Steffen
    Choy, Ernest
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (07) : 497 - 510
  • [48] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Edwards, Christopher J.
    Sawant, Ruta
    Garg, Vishvas
    Du, Ella X.
    Friedman, Alan
    Betts, Keith A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 167 - 181
  • [49] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Christopher J. Edwards
    Ruta Sawant
    Vishvas Garg
    Ella X. Du
    Alan Friedman
    Keith A. Betts
    Rheumatology and Therapy, 2021, 8 : 167 - 181
  • [50] Pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy plus /-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    LUNG CANCER, 2021, 155 : 175 - 182
12345